CD8 + CD28 − regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyLetter Published on 2024-06-032024-09-05 Journal: Leukemia [Category] update2024, [키워드] Myeloma Phase III trials [DOI] 10.1038/s41375-024-02290-y PMC 바로가기 [Article Type] Letter
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM studyarticle Published on 2023-12-112024-09-05 Journal: Blood Cancer Journal [Category] update2024, [키워드] Myeloma [DOI] 10.1038/s41408-023-00944-1 PMC 바로가기 [Article Type] article
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myelomaarticle Published on 2023-12-072024-09-05 Journal: Blood Cancer Journal [Category] update2024, [키워드] Epidemiology Myeloma [DOI] 10.1038/s41408-023-00901-y PMC 바로가기 [Article Type] article
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patientsArticle Published on 2023-12-042024-09-05 Journal: Leukemia [Category] update2024, [키워드] Infectious diseases Myeloma Translational research [DOI] 10.1038/s41375-023-02070-0 PMC 바로가기 [Article Type] Article
Distal Chronic Inflammatory Demyelinating Polyneuropathy Following COVID-19 Vaccination in a Patient with Solitary Plasmacytoma: A Case Report and Literature ReviewCase Report Published on 2023-08-152024-09-04 Journal: Internal medicine (Tokyo, Japan) [Category] 대상포진, [키워드] anti-ganglioside antibody CIDP COVID-19 Myeloma plasmacytoma vaccination [DOI] 10.2169/internalmedicine.1365-22 PMC 바로가기 [Article Type] Case Report
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaarticle Published on 2023-07-252024-09-05 Journal: Blood Cancer Journal [Category] update2024, [키워드] Combination drug therapy Myeloma [DOI] 10.1038/s41408-023-00882-y PMC 바로가기 [Article Type] article
Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coacharticle Published on 2023-05-202024-09-05 Journal: Pilot and Feasibility Studies [Category] update2024, [키워드] E-coach E-health medication Myeloma supportive care [DOI] 10.1186/s40814-023-01307-0 PMC 바로가기 [Article Type] article
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective AnalysisArticle Published on 2022-12-292024-09-04 Journal: Clinical lymphoma, myeloma & leukemia [Category] 대상포진, [키워드] Carfilzomib Cyclophosphamide daratumumab Myeloma plasma cell leukemia [DOI] 10.1016/j.clml.2022.12.004 PMC 바로가기 [Article Type] Article
Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasiasArticle Published on 2022-11-012022-11-15 Journal: British Journal of Haematology [Category] 진단, [키워드] age anti-CD38 antibodies antibody Antibody Response Antibody testing antibody titres Antigen binding domain BNT162b2 breadth Cell comparable coronavirus disease correlated COVID-19 COVID-19 vaccination demonstrated detectable dose dyscrasia elicit Genome healthy humoral immune immunization Immunocompromised Immunoglobulin Increasing initial Intervention investigated JNJ-78436735 maturation median mRNA vaccine mRNA-1273 Myeloma of BNT162b2 Patient patient population plasma Population proportion receiving Region response spike-specific T-cell Spike-specific T-cell responses Surface glycoprotein T-cell T-cell receptor T-cell Response TCR tested therapy underlying disease vaccination Vaccines [DOI] 10.1111/bjh.18434 PMC 바로가기
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With MyelomaArticle Published on 2022-09-102022-11-15 Journal: Journal of clinical oncology : official journal of [Category] SARS, 변종, 진단, 치료기술, [키워드] affected analyzed antibody B-cell malignancy BNT162b2 Booster vaccine Characteristics Critical Delta detect detectable determinant disease environmental exposure Factors greater hosts Immunocompromised implication increased risk induction initial lack Live virus Moderna MONITOR Mortality mRNA1273 much lower Multiple myeloma Myeloma NAb neutralization neutralize neutralizing antibody neutralizing capacity nucleocapsid Patient patients Pseudovirus neutralization assay quantified RBD receiving response SARS CoV-2 Seroconversion Serologic response significantly spike receptor-binding domain the vaccine Treatment vaccination Vaccine vaccine-induced antibody variant viral neutralization virus virus-neutralizing were measured [DOI] 10.1200/JCO.21.02257 PMC 바로가기